Navigation Links
3SBio and Ascentage Pharma Form Strategic Alliance to Research, Develop and Commercialize Cancer Therapeutics
Date:2/11/2010

SHENYANG, China, Feb. 11 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX) ("3SBio" or "the Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, and Ascentage Pharma Group Corporation, Ltd. ("Ascentage Pharma") announced today that they have formed a strategic alliance to research, develop and commercialize best-in-class targeted cancer therapeutics focusing on programmed cell death, or apoptosis. The alliance will leverage Ascentage Pharma's expertise in structure-based small molecule design, lead optimization and preclinical development with 3SBio's proven drug development and commercialization capabilities in China.

Under the terms of the agreement, 3SBio will make a US$3 million equity investment in Ascentage Pharma. The investment will be used to fund Ascentage Pharma's R&D programs. 3SBio will have the exclusive right to develop and commercialize cancer therapeutics in China that are discovered through Ascentage Pharma programs, while Ascentage Pharma will retain the rights to the rest of the world and receive future milestone and royalty payments from any sales by 3SBio in China.

"The collaboration with Ascentage Pharma represents a key strategic initiative for 3SBio to develop our pipeline in the area of cancer therapeutics," said Dr. Jing Lou, CEO of 3SBio. "This investment allows 3SBio to gain access to the best external science and small molecule drug discovery platform in China."

"Apoptosis targeted small molecule has the potential to play a key role in the next generation of highly effective targeted cancer drugs," said Dr. Dajun Yang, CEO of Ascentage Pharma. "We believe that this 'win-win' collaboration will generate innovative medicines that benefits patients worldwide."

About 3SBio Inc.

3SBio Inc. is a leading, fully integrated biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, primarily in China. For more information, please visit 3SBio on the web at http://www.3sbio.com .

About Ascentage Pharma Group Corporation, Ltd.

Ascentage Pharma is a recent spin-off of Ascenta (Shanghai) R&D Center, a wholly owned subsidiary of Ascenta Therapeutics, Inc. which was established in August 2005. The new company, including the team and facility, became independent in the summer 2009. The team has an established track record in late stage discovery, preclinical and IND enabling work, working with both China's SFDA and the US FDA. Ascentage Pharma will focus on oncology new chemical entity (NCE) drug R&D using cutting edge apoptosis technology, building on molecules and compounds licensed from the University of Michigan. The company aims to develop best-in-class targeted therapeutics for the unmet medical needs of both China and global markets.

Safe Harbor Statement

This press release contains statements of a forward-looking nature. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. The accuracy of these statements may be impacted by a number of business factors and uncertainties that could cause actual results to differ materially from those projected or anticipated, including factors related to: the risk that Ascentage Pharma's R&D programs will not result in therapeutics which produce satisfactory results in clinical trials or obtain SFDA approval due to the inherent uncertainty of the timing and success of pharmaceutical research and development projects or that Ascentage will require additional funding to develop new therapeutics; the risk that 3SBio may not be successful in commercializing any therapeutics developed by Ascentage Pharma pursuant to their strategic alliance due to difficulties or delays in manufacturing, lack of demand by hospitals and doctors or other factors; the risk of intellectual property disputes arising with third parties in connection with newly developed therapeutics; the risk that the strategic alliance will not continue for its full term for whatever reason; uncertainties regarding 3SBio's ability to obtain favorable insurance coverage and pricing for any therapeutics developed by Ascentage Pharma; changes in the healthcare industry in China, including changes in the healthcare policies and regulations of the P.R.C. government and changes in the healthcare insurance sector in the P.R.C.; fluctuations in general economic and business conditions in China; and other risks outlined in 3SBio's filings with the Securities and Exchange Commission. 3SBio does not undertake any obligation to update this forward-looking information, except as required under applicable law.

    For more information, please contact:

    3SBio Inc.
     Bo Tan
     Chief Financial Officer
     Tel:   +86-24-2581-1820
     Email: ir@3SBio.com

     Tom Folinsbee
     Director of Investor Relations
     Tel:   +852-8191-6991
     Email: ir@3SBio.com

SOURCE 3SBio Inc.

RELATED LINKS
http://www.3sbio.com

'/>"/>

SOURCE 3SBio Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. 3SBio Inc. to Present at the UBS Global Life Sciences Conference
2. 3SBio Inc. to Hold Annual General Meeting
3. 3SBio Inc. Schedules 2007 Third Quarter Earnings Release On Tuesday, November 13, 2007
4. 3SBio Inc. To Present at the 19th Annual Piper Jaffray Health Care Conference
5. 3SBio Inc. Announces Appointment of Kevin Sow Peng Teo as Chief Financial Officer
6. 3SBio Inc. to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
7. 3SBio Inc. Schedules 2007 Fourth Quarter and Full Year Earnings Release on Wednesday, February 20, 2008
8. 3SBio Inc. Announces Change to the Board of Directors
9. 3SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results
10. 3SBio Inc. Announces Promotion of David Chen as Chief Operating Officer
11. 3SBio Inc. Approves Share Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... , Jan. 24, 2017 Vivonoetics Inc., ... announced today that in partnership with Great Lakes ... to the Roche FIREFISH study.    ... respiratory insufficiency due to progressive respiratory muscle weakness ... the spinal cord. This weakness results in ineffective ...
(Date:1/24/2017)... Jan. 24, 2017 Reha Technology USA ... Boston . The need for Robotic technology in ... is widely accepted in the surgical space. Project Walk – ... to traditional therapy and adding technology to their continuum of care. ... higher gait training repetitions which has been shown to improve gait ...
(Date:1/24/2017)... , Jan. 24, 2017 Relmada Therapeutics, Inc. ... the treatment of central nervous system (CNS) diseases, is ... and a recent meeting with the U.S. Food and ... the clinical development of LevoCap ER (REL-1015, levorphanol extended ... new drug application (NDA) filing is achievable.   ...
(Date:1/24/2017)... 2017  Applied BioMath ( www.appliedbiomath.com ), ... drug research and development, today announced their ... and Next-Generation Biologics: Innovative Strategies for Optimally ... PhD, Senior Scientist at Applied BioMath will ... mechanistic determinants of antibody drug-conjugate pharmacokinetics using ...
Breaking Biology Technology:
(Date:1/24/2017)... 24, 2017 Biopharm Reports has carried ... use of nuclear magnetic resonance spectroscopy (NMR). This ... profiled current practices, developments, trends and end-user plans ... growth and opportunities. These areas include growth in ... needs and innovation requirements, hyphenated NMR techniques, main ...
(Date:1/24/2017)... -- It sounds simple and harmless—an electronic sensor attached ... and alerts parents on their smart phones if, ... But pediatric experts argue that such devices may ... of medical benefits, especially to healthy babies. ... of healthy babies, promising peace of mind about ...
(Date:1/23/2017)... 23, 2017  The latest mobile market research from ... dropped dramatically. The quarterly average price of a biometric ... in Q4 2016.  There are now 120 sub-$150 models ... up from just 28 a year ago at an ... Maxine Most , Acuity Market Intelligence Principal, "Biometric ...
Breaking Biology News(10 mins):